Literature DB >> 12949994

Blood-brain barrier efflux transport.

Pamela L Golden1, Gary M Pollack.   

Abstract

Efflux transport at the blood-brain barrier (BBB) limits the brain tissue exposure to a variety of potential therapeutic agents, including compounds that are relatively lipophilic and would be predicted to permeate the endothelial lining of the brain microvasculature. Recent advances in molecular and cell biology have led to identification of several specific transport systems at the blood-brain interface. Refinement of classical pharmacokinetic experimentation has allowed assessment of the structural specificity of transporters, the impact of efflux transport on brain tissue exposure, and the potential for drug-drug interactions at the level of BBB efflux transport. The objective of this minireview is to summarize efflux transporter characteristics (location, specificity, and potential inhibition) for transport systems identified in the BBB. A variety of experimental approaches available to ascertain or predict the impact of efflux transport on net brain tissue uptake of substrates also are presented. The potential impact of efflux transport on the pharmacodynamics of agents acting in the central nervous system are illustrated. Finally, general issues regarding the role of identifying efflux transport as part of the drug development process are discussed. Copyright 2003 Wiley-Liss, Inc. and the American Pharmacists Association

Mesh:

Substances:

Year:  2003        PMID: 12949994     DOI: 10.1002/jps.10424

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  28 in total

1.  In vitro and in vivo investigation of dexibuprofen derivatives for CNS delivery.

Authors:  Xuan Zhang; Xing Liu; Tao Gong; Xun Sun; Zhi-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

2.  CNS Anticancer Drug Discovery and Development Conference White Paper.

Authors:  Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

3.  Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.

Authors:  Hazem E Hassan; Alan L Myers; Andrew Coop; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2009-12       Impact factor: 3.534

Review 4.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

5.  QSAR modeling of the blood-brain barrier permeability for diverse organic compounds.

Authors:  Liying Zhang; Hao Zhu; Tudor I Oprea; Alexander Golbraikh; Alexander Tropsha
Journal:  Pharm Res       Date:  2008-06-14       Impact factor: 4.200

Review 6.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.

Authors:  Sagar Agarwal; Ramola Sane; Rajneet Oberoi; John R Ohlfest; William F Elmquist
Journal:  Expert Rev Mol Med       Date:  2011-05-13       Impact factor: 5.600

7.  Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier.

Authors:  Corbin J Bachmeier; Timothy J Spitzenberger; William F Elmquist; Donald W Miller
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

8.  Acute effects of short-chain alkylglycerols on blood-brain barrier properties of cultured brain endothelial cells.

Authors:  P Hülper; S Veszelka; F R Walter; H Wolburg; P Fallier-Becker; J Piontek; I E Blasig; M Lakomek; W Kugler; M A Deli
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

9.  Monitoring proteins using in vivo near-infrared time-domain optical imaging after 2-O-hexyldiglycerol-mediated transfer to the brain.

Authors:  Petra Hülper; Christian Dullin; Wilfried Kugler; Max Lakomek; Bernhard Erdlenbruch
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

10.  Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.

Authors:  Soumyajit Majumdar; Ketan Hippalgaonkar; Ramesh Srirangam
Journal:  Drug Metab Dispos       Date:  2009-04-30       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.